Tags

Type your tag names separated by a space and hit enter

Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review.
Int J Pharm. 2020 Jun 15; 583:119385.IJ

Abstract

Arsenic trioxide (As2O3), a front-line therapeutic agent against acute promyelocytic leukemia, has a broad spectrum against malignancies. Unfortunately, the clinical application of As2O3 in treating hematological cancers has not been transformed to solid tumors, for its dose-limited toxicity and undesirable pharmacokinetics. The ordinary As2O3 loaded nanodrugs (such as liposomes, polymer micelles, albumin-based nanodrugs, and silica-based nanodrugs, etc.) still could not fuel up pharmaceuticals and eradicate toxicity for low delivery efficiency caused by the instability and severe drug leakage of formulations during circulation. Recently, the approach of forming and delivering arsenic-metal complexes which will dissociate in the tumoral environment caught our mind. This is the most effective strategy to reduce drug leakage in circulation and accumulate arsenite ions in tumor sites, therefore promote the anti-tumor effect and lighten the toxicity of the drug. This review aims to explain the formation mechanism of arsenic-metal nanocomposites and summarize the constructing strategies of the arsenic-metal nanocomplexes (arsenic-nickel, arsenic-manganese, arsenic-platinum, arsenic-gadolinium, arsenic-zinc, and arsenic-iron nanobins) loaded nanodrugs for solid tumor therapy. Furthermore, the expectations and challenges of arsenic-metal complexes containing nanodrugs for cancer therapy in the future were discussed.

Authors+Show Affiliations

Department of Pharmacy, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.Department of Pharmacy, Zhejiang Chinese Medicine and Western Medicine Integrated Hospital, Hangzhou 310003, China.College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.Department of Pharmacy, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.Department of Pharmacy, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.Department of Pharmacy, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China. Electronic address: lifanzhu@zcmu.edu.cn.Department of Pharmacy, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China. Electronic address: chzheng@zju.edu.cn.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32376447

Citation

Fei, Weidong, et al. "Construction of Arsenic-metal Complexes Loaded Nanodrugs for Solid Tumor Therapy: a Mini Review." International Journal of Pharmaceutics, vol. 583, 2020, p. 119385.
Fei W, Li C, Tao J, et al. Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review. Int J Pharm. 2020;583:119385.
Fei, W., Li, C., Tao, J., Cai, X., Yao, W., Ye, Y., Zhang, Y., Yao, Y., Song, Q., Li, F., & Zheng, C. (2020). Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review. International Journal of Pharmaceutics, 583, 119385. https://doi.org/10.1016/j.ijpharm.2020.119385
Fei W, et al. Construction of Arsenic-metal Complexes Loaded Nanodrugs for Solid Tumor Therapy: a Mini Review. Int J Pharm. 2020 Jun 15;583:119385. PubMed PMID: 32376447.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review. AU - Fei,Weidong, AU - Li,Chaoqun, AU - Tao,Jiaoyang, AU - Cai,Xinjun, AU - Yao,Wendong, AU - Ye,Yiqing, AU - Zhang,Yue, AU - Yao,Yao, AU - Song,Qianqian, AU - Li,Fanzhu, AU - Zheng,Caihong, Y1 - 2020/05/04/ PY - 2020/03/19/received PY - 2020/04/27/revised PY - 2020/04/28/accepted PY - 2020/5/8/pubmed PY - 2020/5/8/medline PY - 2020/5/8/entrez KW - Arsenic-metal complexes KW - Drug delivery KW - Formation mechanism KW - Solid tumor KW - Tumoral environment SP - 119385 EP - 119385 JF - International journal of pharmaceutics JO - Int J Pharm VL - 583 N2 - Arsenic trioxide (As2O3), a front-line therapeutic agent against acute promyelocytic leukemia, has a broad spectrum against malignancies. Unfortunately, the clinical application of As2O3 in treating hematological cancers has not been transformed to solid tumors, for its dose-limited toxicity and undesirable pharmacokinetics. The ordinary As2O3 loaded nanodrugs (such as liposomes, polymer micelles, albumin-based nanodrugs, and silica-based nanodrugs, etc.) still could not fuel up pharmaceuticals and eradicate toxicity for low delivery efficiency caused by the instability and severe drug leakage of formulations during circulation. Recently, the approach of forming and delivering arsenic-metal complexes which will dissociate in the tumoral environment caught our mind. This is the most effective strategy to reduce drug leakage in circulation and accumulate arsenite ions in tumor sites, therefore promote the anti-tumor effect and lighten the toxicity of the drug. This review aims to explain the formation mechanism of arsenic-metal nanocomposites and summarize the constructing strategies of the arsenic-metal nanocomplexes (arsenic-nickel, arsenic-manganese, arsenic-platinum, arsenic-gadolinium, arsenic-zinc, and arsenic-iron nanobins) loaded nanodrugs for solid tumor therapy. Furthermore, the expectations and challenges of arsenic-metal complexes containing nanodrugs for cancer therapy in the future were discussed. SN - 1873-3476 UR - https://www.unboundmedicine.com/medline/citation/32376447/Construction_of_arsenic-metal_complexes_loaded_nanodrugs_for_solid_tumor_therapy:_A_mini_review L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5173(20)30369-0 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.